Pharmacological Mechanism of NRICM101 for COVID-19 Treatments by Combined Network Pharmacology and Pharmacodynamics.

Int J Mol Sci

Department of Bioenvironmental Systems Engineering, National Taiwan University, Taipei 10617, Taiwan.

Published: December 2022

Symptom treatments for Coronavirus disease 2019 (COVID-19) infection and Long COVID are one of the most critical issues of the pandemic era. In light of the lack of standardized medications for treating COVID-19 symptoms, traditional Chinese medicine (TCM) has emerged as a potentially viable strategy based on numerous studies and clinical manifestations. Taiwan Chingguan Yihau (NRICM101), a TCM designed based on a medicinal formula with a long history of almost 500 years, has demonstrated its antiviral properties through clinical studies, yet the pharmacogenomic knowledge for this formula remains unclear. The molecular mechanism of NRICM101 was systematically analyzed by using exploratory bioinformatics and pharmacodynamics (PD) approaches. Results showed that there were 434 common interactions found between NRICM101 and COVID-19 related genes/proteins. For the network pharmacology of the NRICM101, the 434 common interacting genes/proteins had the highest associations with the interleukin (IL)-17 signaling pathway in the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Moreover, the tumor necrosis factor (TNF) was found to have the highest association with the 30 most frequently curated NRICM101 chemicals. Disease analyses also revealed that the most relevant diseases with COVID-19 infections were pathology, followed by cancer, digestive system disease, and cardiovascular disease. The 30 most frequently curated human genes and 2 microRNAs identified in this study could also be used as molecular biomarkers or therapeutic options for COVID-19 treatments. In addition, dose-response profiles of NRICM101 doses and IL-6 or TNF-α expressions in cell cultures of murine alveolar macrophages were constructed to provide pharmacodynamic (PD) information of NRICM101. The prevalent use of NRICM101 for standardized treatments to attenuate common residual syndromes or chronic sequelae of COVID-19 were also revealed for post-pandemic future.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740625PMC
http://dx.doi.org/10.3390/ijms232315385DOI Listing

Publication Analysis

Top Keywords

nricm101
9
mechanism nricm101
8
nricm101 covid-19
8
covid-19 treatments
8
network pharmacology
8
434 common
8
frequently curated
8
covid-19
7
pharmacological mechanism
4
treatments
4

Similar Publications

Amidst growing concerns over COVID-19 aftereffects like fatigue and cognitive issues, NRICM101, a traditional Chinese medicine, has shown promise. Used by over 2 million people globally, it notably reduces hospitalizations and intubations in COVID-19 patients. To explore whether NRICM101 could combat COVID-19 brain fog, we tested NRICM101 on hACE2 transgenic mice administered the S1 protein of SARS-CoV-2, aiming to mitigate S1-induced cognitive issues by measuring animal behaviors, immunohistochemistry (IHC) staining, and next-generation sequencing (NGS) analysis.

View Article and Find Full Text PDF

The emergence of new SARS-CoV-2 variants with a higher contagious capability and faster transmissible speed has imposed an incessant menace on global health and the economy. The SARS-CoV-2 infection might reoccur and last much longer than expected. Thence, there is a high possibility that COVID-19 can cause long-term health problems.

View Article and Find Full Text PDF

Aim Of The Study: Our hypothesis is that nirmatrelvir can penetrate the blood‒brain barrier and reach effective concentrations in the brain. Furthermore, herbal formulations can help maintain nirmatrelvir levels in the body, suggesting potential interactions between these medications.

Materials And Methods: To investigate this hypothesis, an animal model combining multisite microdialysis, ultrahigh-performance liquid chromatography and tandem mass spectrometry (UHPLC-MS/MS) methods was developed to monitor nirmatrelvir levels in the blood and brain of rats.

View Article and Find Full Text PDF

NRICM101 prevents kainic acid-induced seizures in rats by modulating neuroinflammation and the glutamatergic system.

Int Immunopharmacol

October 2024

School of Medicine, Fu Jen Catholic University, New Taipei City 24205, Taiwan; Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan City 33303, Taiwan. Electronic address:

Article Synopsis
  • The study investigates the effects of the Traditional Chinese medicine formula NRICM101 on epilepsy, specifically its ability to reduce seizures induced by kainic acid (KA) in rats.
  • NRICM101 significantly decreases seizure behavior, neuronal loss, and glutamate levels while enhancing protective proteins in the brain, and its effects are comparable to the established antiseizure drug carbamazepine.
  • The formula also shows promising neuroprotective effects by mitigating inflammation and cell death in the brain without causing harm to the liver or kidneys, suggesting its potential for managing epilepsy.
View Article and Find Full Text PDF

Background: The aim of this study was to assess the efficacy and safety of NRICM101 in hospitalized patients with COVID-19.

Research Design And Methods: We conducted a retrospective study from 20 April 2021 to 8 July 2021, and evaluated the safety and outcomes (mortality, hospital stay, mechanical ventilation, oxygen support, diarrhea, serum potassium) in COVID-19 patients. Propensity score matching at a 1:2 ratio was performed to reduce confounding factors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!